X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3) 3
oncology (3) 3
algorithms (2) 2
care and treatment (2) 2
medicine & public health (2) 2
metastasis (2) 2
nursing (2) 2
nursing research (2) 2
pain medicine (2) 2
pharmacists (2) 2
rehabilitation medicine (2) 2
1st-line treatment (1) 1
abiraterone (1) 1
adverse events (1) 1
afatinib (1) 1
algorithm (1) 1
american society (1) 1
analysis (1) 1
anticoagulants (1) 1
anticoagulation (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
axitinib (1) 1
cancer (1) 1
cancer patients (1) 1
carcinoma, renal cell (1) 1
cardiac arrhythmia (1) 1
cell lung-cancer (1) 1
chemotherapy (1) 1
clinical-experience (1) 1
clinical-practice guidelines (1) 1
complications and side effects (1) 1
corticosteroids (1) 1
development and progression (1) 1
diarrhea (1) 1
disease progression (1) 1
dose-escalation (1) 1
drug resistance (1) 1
egfr (1) 1
exposure (1) 1
health care sciences & services (1) 1
health risk assessment (1) 1
heart (1) 1
hepatocellular-carcinoma (1) 1
lung cancer (1) 1
lung cancer, non-small cell (1) 1
mortality (1) 1
nsclc (1) 1
open-label (1) 1
patient assessment (1) 1
patient compliance (1) 1
patients (1) 1
pharmacokinetics (1) 1
phase-ii (1) 1
phase-iii trial (1) 1
prednisone (1) 1
prescription writing (1) 1
proactive monitoring (1) 1
prostate cancer (1) 1
quantitative analysis (1) 1
rehabilitation (1) 1
renal cell carcinoma (1) 1
resistance (1) 1
side effects (1) 1
skin treatment regimen (1) 1
sorafenib (1) 1
strategic planning (1) 1
sunitinib (1) 1
supportive care (1) 1
thromboembolism (1) 1
titration (1) 1
toxicity (1) 1
tyrosine kinase inhibitor (1) 1
urology & nephrology (1) 1
usage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6_suppl, pp. 458 - 458
458 Background: Previous pharmacologic studies demonstrated that higher sunitinib ( S) exposure is associated with improved clinical outcomes in metastatic... 
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 01/2018, Volume 36, Issue 1, pp. 12.e1 - 12.e6
Previous pharmacologic studies demonstrated that higher sunitinib exposure is associated with improved clinical outcomes in patients with metastatic renal cell... 
Sunitinib | Dose-escalation | Renal cell carcinoma | Toxicity | Disease progression | AXITINIB | PHASE-II | SORAFENIB | CANCER | CLINICAL-EXPERIENCE | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | RESISTANCE | UROLOGY & NEPHROLOGY | TITRATION | EXPOSURE | Antimitotic agents | Carcinoma, Renal cell | Metastasis | Drug resistance | Antineoplastic agents | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 30_suppl, pp. 268 - 268
268 Background: CDK 4/6 Inhibitors such as palbociclib in combination with hormonal therapy are considered the new standard of care for eligible advanced... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 321 - 321
321 Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been used to treat grade 1-2 NETs,... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.